Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup
NCT03705273
Terminated
Study of the palatability and acceptability of dexamethasone oral tablets crushed and placed in apple sauce or pudding in comparison with the IV solution mixed with sugar syrup and given orally. It is hypothesized that dexamethasone tablets crushed and administered in apple sauce or pudding will be more palatable and acceptable for pediatric patients receiving dexamethasone for an acute asthma exacerbation or croup.
Gender:
ALL
Ages:
Between 1 year and 7 years
Trial Updated:
10/11/2021
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Asthma, Croup
Register for Updates
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
NCT01054144
Completed
The purpose of this research is to estimate the effectiveness of a response adapted approach with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed standard risk multiple myeloma. This means that participants will be given the study drug, lenalidomide but depending on how they respond to this drug they may also be given dexamethasone and/or prednisone to help with their treatment.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
10/08/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819
Completed
The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated subjects, and in relapsed subjects with multiple myeloma, as defined by the International Myeloma Working Group (IMWG) criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2021
Locations: Not set, Mobile, Alabama +25 locations
Conditions: Multiple Myeloma
Register for Updates
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04882163
Withdrawn
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2021
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +26 locations
Conditions: Lymphoma, B-Cell
Register for Updates
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT01666210
Completed
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/23/2021
Locations: Chicago Cornea Consultants, Ltd., Hoffman Estates, Illinois
Conditions: Ocular Inflammation and Pain
Register for Updates
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
NCT04050865
Completed
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Vision Institute, Colorado Springs, Colorado +5 locations
Conditions: Allergic Conjunctivitis
Register for Updates
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
NCT02464657
Completed
The goal of this clinical research study is to find the highest tolerable dose of nivolumab that can be give in combination with idarubicin and cytarabine in patients with MDS and AML. The safety and effectiveness of this drug combination will also be studied. This is an investigational study. Nivolumab is not FDA-approved or commercially available. Idarubicin is FDA-approved and commercially available for the treatment of patients with AML. Cytarabine is FDA approved and commercially available... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
NCT01381692
Completed
This randomized phase I/II trial studies the side effects and the best dose of temsirolimus when given together with bortezomib, rituximab, and dexamethasone and to see how well they work compared to bortezomib, rituximab, and dexamethasone alone in treating patients with untreated or relapsed Waldenstrom macroglobulinemia or relapsed or refractory mantle cell or follicular lymphoma. Bortezomib and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2021
Locations: Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado +10 locations
Conditions: Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Register for Updates
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
NCT01965353
Completed
This research study is evaluating an investigational drug called "panobinostat" (LBH589) in combination with the standard agents lenalidomide, bortezomib, and dexamethasone as a possible treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2021
Locations: Brigham and Women's Hospital, Boston, Massachusetts +3 locations
Conditions: Multiple Myeloma in Relapse
Register for Updates
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
NCT01363479
Completed
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that oral palonosetron 0.50 mg is as effective as (non-inferior to) palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2021
Locations: Genesis Cancer Centre, Hot Springs, Arkansas +78 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Register for Updates
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
NCT00299182
Completed
The goal of this clinical research study is to find the highest safe dose of AMG 531 that can be given to treat thrombocytopenia (low platelet counts) in patients who have received chemotherapy. Researchers will also look at the safety and effectiveness of AMG 531. Primary Objectives: 1. To determine the clinical safety and tolerability of AMG 531 administered following chemotherapy (R-HyperCVAD alternating with R-Ara-C/MTX) in patients with non-Hodgkin's lymphoma. 2. To determine an optimal b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2021
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
NCT00792142
Completed
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with thalidomide and dexamethasone may kill any cancer cells that remain after high-dose melphalan and stem cell transplant in patients with multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving bortezomib together w... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
08/17/2021
Locations: City of Hope Medical Center, Duarte, California
Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Register for Updates